Stockpolly
Search
XBIT · NASDAQ · Biotechnology

XBiotech (XBIT)

Develops human-derived monoclonal antibodies through integrated Austin research, clinical development and manufacturing.

$2.20
At close−0.02 (−0.90%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
9811158914663066
Research & development8810137812552555
101211211411
General & administrative101211211411
Other expenses000000000000
Operating income−9−9−11−15−8−9−14−6−6−30−6−6
14123−235031−1
Interest income333322221111
Interest expense000000000000
Other non-operating income−1−4−1−2−32−3−50−3−1−1
Income before tax−7−5−10−13−5−11−11−2−6−27−5−7
Income tax expense000000000000
Net income from continuing operations−7−5−10−13−5−11−11−2−6−27−6−7
Net income−7−5−10−13−5−11−11−2−6−27−6−7
EPS, basic−$0.24−$0.15−$0.33−$0.43−$0.16−$0.34−$0.36−$0.06−$0.20−$0.88−$0.18−$0.22
EPS, diluted−$0.24−$0.15−$0.33−$0.43−$0.16−$0.34−$0.36−$0.06−$0.20−$0.88−$0.18−$0.22
Weighted average shares, basic303030303030303030303030
Weighted average shares, diluted303030303030303030303030
EBITDA−7−4−9−13−4−10−10−1−5−26−5−5
Depreciation & amortization000000000000
EBIT−7−5−10−13−5−10−11−2−6−27−5−5